2024. Personalized Care with DPP4i/SGLT2i Strategy as Initial-Line in the Management of Type 2 Diabetes Mellitus with Cardiovascular Risk: DELPHI Statement. Cardiology and Cardiovascular Medicine. 8, 2 (Mar. 2024), 111–117.